Brevan Howard Capital Management LP Buys 43,270 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Brevan Howard Capital Management LP raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 321.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,749 shares of the biopharmaceutical company's stock after acquiring an additional 43,270 shares during the period. Brevan Howard Capital Management LP's holdings in ACADIA Pharmaceuticals were worth $1,041,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. R Squared Ltd bought a new stake in ACADIA Pharmaceuticals during the 4th quarter worth approximately $47,000. KBC Group NV increased its position in shares of ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 2,044 shares in the last quarter. Globeflex Capital L P acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $168,000. Xponance Inc. bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $186,000. Finally, Vinva Investment Management Ltd acquired a new position in ACADIA Pharmaceuticals in the 4th quarter worth $187,000. 96.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ACAD. StockNews.com raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Morgan Stanley reissued an "equal weight" rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Finally, UBS Group decreased their price objective on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 28th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $24.70.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 3,498 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $14.60, for a total transaction of $51,070.80. Following the completion of the sale, the executive vice president now owns 62,773 shares of the company's stock, valued at approximately $916,485.80. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,994 shares of company stock worth $313,131. Company insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Stock Up 3.0 %

Shares of ACAD stock traded up $0.51 during trading on Friday, reaching $17.44. 2,854,983 shares of the company's stock were exchanged, compared to its average volume of 1,855,937. The firm's fifty day moving average price is $15.83 and its 200-day moving average price is $16.96. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $20.68. The stock has a market capitalization of $2.92 billion, a PE ratio of 22.36 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The company's revenue was up 18.7% on a year-over-year basis. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.